Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 4/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.56 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15241465 | 0.91 | MAPT (0.55) | MAPKAPK2MAPTTP53ALDH1A1ABCG2 | |
| SCHEMBL8025885 | 0.88 | MAPKAPK2 (0.56) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL9401140 | 0.88 | MAPKAPK2 (0.61) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL8025879 | 0.88 | MAPKAPK2 (0.59) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL6242196 | 0.87 | MAPKAPK2 (0.58) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL998246 | 0.85 | MAPKAPK2 (0.59) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL6243057 | 0.85 | MAPKAPK2 (0.65) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL8036166 | 0.84 | MAPKAPK2 (0.58) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL9401138 | 0.84 | MAPKAPK2 (0.59) | MAPKAPK2MAPTTP53SIRT1MAPKAPK5 | |
| SCHEMBL9401154 | 0.83 | MAPKAPK2 (0.61) | MAPKAPK2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| WO-2010138695-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2007101863-A1 | THERAPEUTIC COMBINATION OF A 5HT2 RECEPTOR ANTAGONIST AND OF A 5HT2 RECEPTOR ACTIVATOR | MACEF (FR) | 2007-09-13 | — | — | WO | disclosed |
| EP-1091959-B1 | NOVEL PYRROLO-(3,4-B)QUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICAMENT | MACEF (FR) | 2002-10-23 | — | — | EP | disclosed |
| US-6335346-B1 | HYPNOTIC AGENTS, SEDATIVES | MACEF (FR) | 2002-01-01 | — | — | US | disclosed |
| US-6048868-A | CIRCADIAN RHYTHM DISORDERS; SLEEP DISORDERS; ANTIDEPRESSANTS | CEMAF (FR) | 2000-04-11 | — | — | US | disclosed |
| EP-0781281-A1 | NOVEL MELATONIN AGONIST $g(b)-CARBOLINE DERIVATIVES AND ANALOGS WITH A NAPHTHALENIC STRUCTURE, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | CEMAF (FR) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008490-A1 | NOVEL MELATONIN AGONIST β-CARBOLINE DERIVATIVES AND ANALOGS WITH A NAPHTHALENIC STRUCTURE, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | CEMAF (FR) | 1996-03-21 | — | — | WO | disclosed |
| US-5314908-A | Compounds useful as antiproliferative agents | WHITBY RESEARCH, INC. (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0549916-A2 | Compounds useful as antiproliferative agents | WHITBY RESEARCH, Inc. (US) | 1993-07-07 | — | — | EP | disclosed |
| US-5206377-A | Compounds useful as antiproliferative agents | WHITBY RESEARCH, INC. (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | MAPKAPK2 2851/4885MAPT 3300/4885TP53 15/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | MAPKAPK2 2893/4885MAPT 3328/4885TP53 16/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | MAPKAPK2 2893/4885MAPT 3328/4885TP53 16/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | MAPKAPK2 3046/4885MAPT 2964/4885TP53 1818/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | MAPKAPK2 2957/4885MAPT 2901/4885TP53 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.